C-CAMP startup Bugworks, incubated at C-CAMP since 2014 has truly gone global.
Bugworks who are developing next-generation broad spectrum antibiotics to tackle the global problem of antimicrobial resistance has raised $9 million (approx. ₹62 Cr.) from Japanese venture capital firm University of Tokyo Edge Capital (UTEC), the first time that UTEC has invested in the Indian life sciences market. This comes close on the heels of their prestigious CARB-X funding.
Bugworks plans to utilise these funds for their soon-to-be-started clinical trials.